ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is a U.S.-based medical technology company developing TAEUS, a thermo-acoustic enhanced ultrasound platform designed to measure liver fat at the point of care. The company’s first application targets metabolic disease detection and management, including support for GLP-1 therapy eligibility and monitoring, but it has not yet commercialized the technology or generated revenue.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueThermo-acoustic enhanced ultrasound systems and related software for liver fat measurement.
Clinical applications aimed at detecting and managing metabolic disease biomarkers.
Tools intended to support patient selection and monitoring for GLP-1 therapies.
Planned recurring-access model with monthly fees, upgrades, and maintenance.
Traditional sale of the device to customers that prefer an upfront purchase model.
Customers
ENDRA is targeting clinical buyers that need a simple, point-of-care way to assess liver fat and related metabolic disease risk. Its stated go-to-market approach is a direct sales force selling into four markets, with the product positioned for clinicians and healthcare organizations that want biomarker-based decision support for metabolic disease and GLP-1 management.
Buy TAEUS to measure liver fat quickly in office or clinic settings and support diagnosis.
Use the platform to identify and track biomarkers tied to obesity, NAFLD, and related conditions.
Use the device to help determine eligibility and monitor patients receiving GLP-1 treatments.
May adopt the system for broader ultrasound-based assessment workflows and procedural use cases.
Strategy
ENDRA’s strategy is to complete clinical development and obtain FDA approval for its NAFLD/liver-fat TAEUS system, then commercialize it through a low-barrier subscription model. Management is also emphasizing AI/ML enhancement, smaller form factor, and lower procedure time to improve usability and support adoption, while preserving a traditional sale option for some customers.
Commercial launch depends on proving safety, accuracy, and clinical utility.
Recurring revenue could lower customer adoption barriers and improve visibility.
Better usability and accuracy are needed to compete in point-of-care imaging.
Geography
ENDRA is headquartered in the United States and appears to conduct most of its development, financing, and commercialization planning from there. The company has not disclosed meaningful country revenue because it has not yet commercialized TAEUS, so geographic exposure is currently driven more by U.S. capital markets, regulatory approval, and clinical adoption than by sales mix.
Risks
ENDRA remains pre-revenue and depends on external financing to fund development, so liquidity risk is the dominant business issue. The company also faces regulatory, clinical, and commercialization risk because TAEUS still needs validation and FDA approval, while its new cryptocurrency treasury strategy adds volatility and regulatory uncertainty that is unrelated to the core medical device business.
- Liquidity and going-concern riskImpact: CriticalLikelihood: Low
The company has limited cash and needs additional capital to continue operations and commercialization.
Exposure: Core operations and product development
- Cryptocurrency price and regulatory riskImpact: HighLikelihood: Medium
The company intends to hold digital assets, which can be highly volatile and may face securities-law scrutiny.
Exposure: Treasury assets and future offering proceeds
- Regulatory approval riskImpact: HighLikelihood: Low
TAEUS must obtain FDA approval before broad commercialization of the NAFLD system.
Exposure: Product launch timing and market access
- Clinical validation and adoption riskImpact: High
The platform must prove accuracy, utility, and ease of use versus existing imaging alternatives.
Exposure: Customer adoption and pricing power
Accounting
Judgemental itemsLiability-classified warrants are remeasured each period, creating non-cash gains or losses in earnings.
Impact: Can materially distort net loss from quarter to quarter
Employee and consultant equity awards are a meaningful non-cash expense for a development-stage company.
Impact: Raises operating expenses without affecting cash immediately
Management states additional capital is needed to fund operations through the next twelve months.
Impact: Affects investor assessment of solvency and dilution risk
Management must estimate accrued expenses, equity values, and other reserves in a highly uncertain environment.
Impact: Can change reported liabilities and expenses materially
Similar listed companies
Publicly listed companies with a comparable business focus.
Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances)
Fractyl Health, Inc
GUTS · Surgical & Medical Instruments & Apparatus
Fractyl Health is a U.S.-based metabolic therapeutics company developing device and gene-therapy approaches for obesity and type 2 diabetes.
Edwards Lifesciences Corp
EW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences designs and sells structural heart therapies used to treat advanced cardiovascular disease, with a portfolio centered on transcatheter and surgical valve technologies.
Entrada Therapeutics, Inc.
TRDA · Pharmaceutical Preparations
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access.
Veru Inc
VERU · Pharmaceutical Preparations
MBX Biosciences, Inc.
MBX · Pharmaceutical Preparations
Last updated: 24/09/2026